The ‘Parkinson’s disease treatment Market’ research report provides a succinct analysis on the recent market trends. In addition, the report offers a thorough abstract on the statistics, market estimates and revenue forecasts, which further highlights its position in the industry, in tandem with the growth strategies adopted by leading industry players.
Global Parkinson’s disease treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027
Request for Methodology Report @ https://brandessenceresearch.com/requestMethodology/PostId/62
Parkinson’s disease is a neuro degenerative disorder in which parts of the brain become progressively damaged over many years. It is a type of movement disorder. It occurs when nerve tissue unable to produce a chemical named ’Dopamine’ which is used to send signals that help you move your body. Parkinson’s disease usually developed for aged people i.e. above 60 years, but it can also start earlier. It is more common in men than in women. The cause of Parkinson’s disease is unknown, but researchers think that both genetic and environmental factors are involved. Primary symptoms include tremors, Stiffness, Slowness, impaired balance, mild memory & Thinking problem and shuffling gait. Secondary symptoms include Anxiety, Depression, Fatigue, Low blood pressure, muscle cramp, Speech & communication problem, skin & Dental Problem and Dizziness, and Dementia. Risk of Parkinson’s disease increases with age and the disease mainly affects person over 50 years of age. The development of Parkinson’s disease and the degree of destruction differ from person to person. Many people with Parkinson’s disease live long productive lives, whereas others become disabled much more quickly. As symptoms worsen, it may become difficult to walk, talk, and complete simple tasks. Malnutrition and weight maintenance is common problem for people with Parkinson’s disease. There is no test to diagnose Parkinson’s disease with certainty. Treatment options include medication or surgical treatment. Combination of Levodopa with carbidopa is considered as a gold standard for symptomatic treatment of Parkinson’s disease. Surgical treatment options include deep brain stimulation and Carbidopa/levodopa enteral suspension therapy but surgical therapy is effective only for patients who have previously responded to Levodopa therapy. Commercially available drugs for treatment of Parkinson’s disease are Sinemet, Safinamide, Rotigotine, Ropinirole, Pramiprexol, Amantidine, Cycloset, Parlodel (Bromocriptine Mesylate), Rytary, Azilect, Northera, Stalevo, Comtess/Comtan and others. More than past decade, huge improvement has been made in the treatment of Parkinson’s disease such as identification of new therapeutic targets through genetic research, understanding the common mutations that contribute to Parkinson’s disease etc.
Global Parkinson’s diseases Treatment Market report is segmented on the basis of Medication, Medical devices, End user, Distribution Channels and Geography. Based on Medication Global Parkinson’s disease Treatment Market is classified into Dopamine Precursors, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO (Monoamine Oxidase), Inhibitors and Others (anticholinergics, antihistaminics etc.)
On the basis of Medical Devices Global Parkinson’s disease Treatment Market is classified into Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices and others. On the basis of End User Global Parkinson’s disease Treatment Market is classified into Hospitals, Homecare setting, Clinics and Others. On the basis of Distribution Channel Global Parkinson’s disease Drug Market is classified into Retail Pharmacies, Online Pharmacies, Hospital Pharmacies and Drug Stores.
The regions covered in Global Parkinson’s diseases Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Key Players –
Global Parkinson’s disease Treatment Market reports cover prominent players like Teva Pharmaceuticals, AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Salix Pharmaceuticals, mpax Laboratories, Orion Corporation, Mylan N.V., Cipla Inc., Daiichi Sankyo, Apotex Inc, Impax Laboratories, Lundbeck, Sun Pharma, Wockhardt ,UCB, Valeant Pharmaceuticals Acadia, Abbvie, Zydus Cadilla, Strides, 1 A Pharma, Upsher-Smith, Intas, US World Meds, Dr. Reddy’s, Medtronic plc, Biotie Therapies Corp., Adamas Pharmaceuticals Inc., Akorn Inc., Astellas Pharma Inc., Desitin Arzneimittel GmbH, Endo International plc, Kyowa Hakko Kirin, Newron Pharmaceuticals and Merck.
Market Dynamics –
Global Parkinson’s disease Treatment Market is mainly driven by growing prevalence of Parkinson’s disease and government funding for research on Parkinson’s disease. The increase in number of geriatric population and technological advancements such as combination therapies for prolong action of continuous dopaminergic stimulation drugs, gene therapy, neural transplantation are few other causes which are possible to boost the Parkinson’s disease Treatment market. However some restraints like availability of alternative treatments is expected to hold back market and expiry of patents for several drugs such as Stalevo, Azilect, Rytary, Comtan etc. can cause the termination of Parkinson’s disease Treatment market. High cost of treatment such as 14.4 Billion USD and lack of expertise for early diagnosis is likely to restrict the market growth.
Also lack of novel and successful therapies in the market to reduce the risk of mortality restraints for this market. The opportunities for Global Parkinson’s disease Treatment market includes upcoming technologies like surface EMG (Electromyography) sensors, Pulse oximetry sensors, development in personalized medicine along with huge investment in anti-Parkinson’s drugs research will boost the global Parkinson’s disease Treatment market. Also development of novel drugs and combination therapy with less side effects and better survival rates is expected to increase the global Parkinson’s disease Treatment market.
Regional Analysis –
Europe is likely to achieve the largest share of the global Parkinson’s disease treatment market, which is expected to be followed by North America with a sizeable market share. High knowledge about the treatment, increase in expenditure for Research & Development, favorable medicinal reimbursement regulations and policies, the high occurrence of Parkinson’s disease, the rapidly growing geriatric population and potential medical pipeline products are likely to contribute to the major share of Europe in Global Parkinson’s disease treatment market. The global Parkinson’s disease treatment market in the Asia Pacific is anticipated to develop at a profitable rate. The market share of the global Parkinson’s disease treatment market is to be expected to grasp by China and Japan in the Asia Pacific, due to the large population of elderly people who are affected with Parkinson’s disease.
Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.
Key Benefits –
- Global Parkinson’s disease Treatment Market report covers in depth historical and forecast analysis.
- Global Parkinson’s disease Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
- Global Parkinson’s disease Treatment Market report helps to identify opportunities in market place.
- Global Parkinson’s disease Treatment Market report covers extensive analysis of emerging trends and competitive landscape.
Market Segmentation –
By Medication Analysis
Dopamine Precursor
Peripheral Decarboxylase Inhibitors
COMT (Catechol-O-methyltransferase) Inhibitors
MAO(monoamine oxidase) Inhibitors
Others (anticholinergics, antihistaminics etc.)
By Medical Devices Analysis
Deep Brain Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices
Others
By End User Analysis
Hospitals
Clinics
Homecare setting
Others
By Distribution Channel
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Drug Store
Get Full Report: https://brandessenceresearch.com/chemical-materials/parkinsons-disease-treatment-market
About us: Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at sales@brandessenceresearch.com
Jesse Pitts has been with the Global Banking & Finance Review since 2016, serving in various capacities, including Graphic Designer, Content Publisher, and Editorial Assistant. As the sole graphic designer for the company, Jesse plays a crucial role in shaping the visual identity of Global Banking & Finance Review. Additionally, Jesse manages the publishing of content across multiple platforms, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune.